Dysregulation of the FGF21-adiponectin axis in a large cohort of patients with severe obesity and liver disease

dc.contributor.authorCastañé Vilafranca, Helena
dc.contributor.authorJiménez Franco, Andrea
dc.contributor.authorOnoiu, Alina Iuliana
dc.contributor.authorCambra Cortés, Vicente
dc.contributor.authorHernández Aguilera, Anna
dc.contributor.authorParada Domíngues, David
dc.contributor.authorRiu, Francisco
dc.contributor.authorZorzano Olarte, Antonio
dc.contributor.authorCamps, Jordi
dc.contributor.authorJoven, Jorge
dc.date.accessioned2025-10-10T11:42:13Z
dc.date.available2025-10-10T11:42:13Z
dc.date.issued2025-09-02
dc.date.updated2025-10-09T10:37:16Z
dc.description.abstractWe investigated the impact of liver damage on systemic inter-organ communication in an extensive observational case-control study of 923 patients with severe obesity and biopsy-confirmed metabolic dysfunction-associated steatotic liver disease (MASLD) or metabolic dysfunction-associated steatohepatitis (MASH) undergoing bariatric surgery. Using a comprehensive panel of circulating organokines, including fibroblast growth factor (FGF) 19, FGF21, adiponectin, galectin-3, irisin, and leptin, along with choline metabolites, we characterized metabolic signaling patterns associated with liver disease severity. Compared to controls, patients with MASLD/MASH exhibited significantly lower levels of FGF19, choline, and trimethylamine, while FGF21, galectin-3, irisin, and leptin were elevated. Sex-specific alterations in leptin and adiponectin were observed in patients with severe obesity but not in controls. Network analysis revealed a complex and individualized interplay among organokines, shaped by age, sex, and anthropometric factors. Despite this complexity, a dysregulation of the FGF21-adiponectin axis was associated with more advanced liver involvement. The large cohort and comprehensive organokine profiling studied provide valuable insights into the role of the FGF21-adiponectin axis on systemic metabolic alterations in severe obesity and their potential clinical implications.
dc.format.extent20 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idimarina6747343
dc.identifier.issn1422-0067
dc.identifier.pmid40943431
dc.identifier.urihttps://hdl.handle.net/2445/223588
dc.language.isoeng
dc.publisherMDPI
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/ijms26178510
dc.relation.ispartofInternational Journal of Molecular Sciences, 2025, vol. 26, num. 17, 8510
dc.relation.urihttps://doi.org/10.3390/ijms26178510
dc.rightscc-by (c) Castañé Vilafranca, Helena et al., 2025
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.sourceArticles publicats en revistes (Bioquímica i Biomedicina Molecular)
dc.subject.classificationMalalties del fetge
dc.subject.classificationTrastorns del metabolisme
dc.subject.otherLiver diseases
dc.subject.otherDisorders of metabolism
dc.titleDysregulation of the FGF21-adiponectin axis in a large cohort of patients with severe obesity and liver disease
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
IntJMolSciences_Castane_2025.pdf
Mida:
3.6 MB
Format:
Adobe Portable Document Format